On Thursday, AN2 Therapeutics, Inc. (NASDAQ:ANTX) released topline results from the Phase 2 part of the EBO-301 Phase 2/3 study of epetraborole on top of an optimized background regimen (OBR) in ...
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron ...
MENLO PARK, Calif.-- (BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious ...
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
AN2 Therapeutics (ANTX) added ~7% in the premarket on Thursday after posting results from two early-stage studies evaluating AN2-502998, its experimental therapy for a parasitic infection known as ...
AN2 Therapeutics Inc (NASDAQ:ANTX) has voluntarily paused Phase 3 enrollment in the Phase 2/3 trial (EBO-301) evaluating epetraborole in treatment-refractory Mycobacterium Avium Complex (MAC) lung ...
Pfizer executives thought they had a blockbuster in waiting after inking a $5.2 billion deal to acquire Anacor Pharmaceuticals and its atopic dermatitis drug candidate. The product won FDA approval in ...
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry ...
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results